2018 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle
12/11/18Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle   Strong anti-pruritic (itch) effect as measured by improvement on the pruritus (itch) numeric rating scale (NRS) compared to vehicle Clinical data additive to established non-clinical results supporting nitric oxide’s role in affecting the underlying immunology of atopic dermatitis MORRISVILLE, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- No... 
12/10/18Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05) Statistically significant reductions in molluscum lesions as early as Week 2 with 12% once-daily No quantifiable levels of systemic exposure detected for SB206 12% twice-daily or once-daily following 12 weeks of treatment A once-daily, at-home, caregiver-applied topical therapy with a clear treatment benefit, if approved, would satisfy an important patient-car... 
11/20/18Novan to Present at Piper Jaffray 30th Annual Healthcare Conference
MORRISVILLE, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Paula Brown Stafford, Chief Development Officer, and Nathan Stasko, President and Chief Scientific Officer, are scheduled to participate in a fireside chat at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018, at 12:00 p.m. Eastern Time, in New York. Audio of the presentation will be webcast live and can be accessed through the Investor... 
11/14/18Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle group Clear treatment effect observed as early as Week 4 in the percent reduction of molluscum lesions Attractive safety and tolerability profile, a critical and highly appealing feature for a predominantly childhood disease SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, i... 
11/12/18Novan Announces Corporate Update Conference Call and Webcast
MORRISVILLE, N.C., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, November 14, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The... 
11/01/18Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in Dermatology SB206 was efficacious and well tolerated in the trial Advancement of the late stage clinical asset for external genital warts will be a priority for the recently created Women’s Health Business Unit MORRISVILLE, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clini... 
10/25/18Novan Creates Dedicated Women’s Health Business Unit
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical cancer where 70% of cases have been conclusively linked to HPV Novan partners with Health Decisions, a specialist CRO whose distinctive track record includes managing more than 150 trials in women-only indications Previously announced Phase 2 data for the treatment of external genital warts... 
10/16/18Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidates Extension of capacity complements existing internal operations, proprietary technological knowledge, intellectual property strategy and production skills Agreement aligns with and supports global business development strategy   MORRISVILLE, N.C., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Com... 
10/08/18Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next 12 months Milestone and royalty payments due with clinical, regulatory and commercial progression Japan, the world’s 2nd largest dermatology market, remains a strategic focus for Novan Novan continues to explore additional geographic markets and other business opportunities MORRISVIL... 
10/01/18Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
Trial enrollment completed meaningfully ahead of schedule Top line results targeted to be communicated no later than mid-November Favorable and consistent safety profile of SB206 enabled escalation to highest, 12% dose MORRISVILLE, N.C., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that enrollment in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum cont... 
09/24/18Novan Receives FDA Guidance for SB204 and Acne Indication
Written minutes received from Type C meeting with FDA Moderate-to-severe patient pathway re-affirmed Additional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced receipt of written meeting minutes from a Type C meeting held with the U.S. Food and Drug Administration (FDA) in the second quarter of 2018. As previously communicated, receipt of the meeting mi... 
08/20/18Novan Announces Promising Clinical Results with SB414
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide therapeutic has the potential to realize disease modification The combination of clinical and biomarker evidence supports progressing nitric oxide-based treatments for multiple inflammatory skin diseases, including, but not limited to, atopic dermatitis, psoriasis and acne rosacea These outc... 
08/08/18Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filing New incentive plan is aligned with the achievement of two specific stockholder value targets and is intended to replace annual employee equity grants CEO employment contract agreed; foundation centered on creating stockholder value MORRISVILLE, N.C., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today provided a comprehensive business update in its For... 
06/13/18Novan to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., June 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that members of management are scheduled to attend the 2018 Cantor Dermatology & Aesthetics Summit and the 2018 JMP Securities Life Sciences Conference, each in New York, N.Y., on June 19 and June 20 and 21, respectively. Dr. Nathan Stasko, President and Chief Scientific Officer, is scheduled to participate in a panel session and members of management are expecte... 
06/01/18Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MORRISVILLE, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today reported that the Compensation Committee of Novan’s Board of Directors granted stock options to purchase an aggregate of 100,500 shares of its common stock to four newly-hired employees with a grant date of May 31, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Novan in accordance with Nasdaq Listing Rule 5635(c)(4). ... 
05/17/18SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
Novan to Present Clinical Data from SB208 Onychomycosis Development Program at International Investigative Dermatology Meeting MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s onychomycosis development program with SB208 gel demonstrated an enhanced nail growth rate in adult females and will be presented May 19, 2018 at the International Investigative Dermatology meeting in Orlando, Florida. ... 
05/15/18Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be presented at International Investigative Dermatology Meeting MORRISVILLE, N.C., May 15, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today is providing an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic ... 
04/12/18Novan Advances Organization and Strengthens Leadership Team
CEO Role No Longer “Interim” Clinical Operations Role Established Finance Team Positioned for the Future MORRISVILLE, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced a number of key leadership and talent advancements that add to the existing foundation of the Company and enable its continued progress across key areas. Kelly Martin, who was appointed interim Chief Executive Officer (CEO) in June of 2017, will no longer be... 
03/29/18Novan Announces Corporate Update Conference Call and Webcast
MORRISVILLE, N.C., March 29, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Thursday, April 12, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The ph... 
02/21/18Dr. Eugene Sun Appointed to Novan Board of Directors
Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEO Will provide expert perspective on the clinical application of the underlying nitric oxide science Will chair newly formed Research and Development Committee   MORRISVILLE, N.C., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Eugene Sun, M.D., has been appointed to the Company’s Board of Directors, effective Feb... 
02/13/18Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
Late-breaking Presentation by Dr. Adelaide Hebert at 2018 AAD Annual Meeting MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term safety trial with SB204 for the treatment acne vulgaris will be presented during a Late-breaking Research forum at the 2018 Annual Meeting of the American Academy of Dermatology, or AAD, in San Diego, California. Newly repor... 
01/25/18Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus. There is currently no FDA-approved treatment for the molluscum indication."Broadening Novan's clinical development pipeline to include the ... 
01/11/18Novan Announces Closing of Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced that it has closed its previously announced underwritten public offering.  The terms of the completed offering are consistent with the terms which were outlined in the Company's press release on January 5, 2018.  The net proceeds to the Company from this offering are expected to be approximately $35.2 million, after deducting underwriting discounts and commissions and ot... 
01/11/18Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Topical Nitric Oxide-Releasing Gel Shows Antifungal Activity in Tinea Pedis Infections MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based gel under development for the treatment of fungal infections of the skin and nails, such as tinea pedis, or athlete’s foot, and onychomycosis, will be presented at the Winter Clinical Dermatology Conference to be ... 
01/05/18Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's underwritten offering of 10 million shares of its common stock and accompanying warrants to purchase up to 10 million shares of common stock with an exercise price of $4.66. The shares and warrants are being sold at a public offering price of $3.80 per share and accompanying warrant. The gross proceeds from this offering to Novan are expected to... 
01/04/18Novan Announces Proposed Public Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. Piper Jaffray & Co. is acting as the sole book-running manager for the offering. The securities described above are being offered by Novan pursuant to a shelf registrat...